Physician

Ahmad Shaker, M.D.

According to 2025 Medicare claims, Ahmad Shaker, M.D. (NPI: 1174767917) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is BAYCARE MEDICAL GROUP, INC. (NPI: 1043269871; TIN: 593140335) and primary practice location at 33705-1407. Shaker is affiliated with the Pearl Network, LLC (ACO ID: D0243), participating under the REACH model.

Shaker's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 700 traditional Medicare patients, billed 2,868 HCPCS/CPT codes, and received $266,328 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,811 prescription claims across 338 beneficiaries totaling $5,479,474 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 24 claims. Open Payments data shows 3 records totaling $611. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $756,964 to $266,328. In contrast, Part D prescription costs have moved sharply higher in recent years, from $12,488 to $5,479,474. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	358	115,611	$756,964
2017	534	193,402	$2,037,647
2018	613	87,174	$913,052
2019	677	2,551	$232,926
2020	694	2,557	$235,446
2021	696	2,568	$270,665
2022	760	2,740	$296,539
2023	688	2,369	$251,916
2024	700	2,868	$266,328

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	33	63	$12,488
2016	241	986	$858,313
2017	249	1,270	$2,001,547
2018	231	1,137	$1,786,265
2019	213	1,291	$1,947,518
2020	238	1,442	$2,359,559
2021	299	1,862	$3,454,664
2022	361	2,124	$4,838,704
2023	331	1,922	$4,619,924
2024	338	1,811	$5,479,474

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	17	$3,020
2021	N/R	16	$2,354
2022	N/R	12	$758
2023	N/R	24	$6,932
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	161	190	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	238	776	$133
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	167	541	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	392	668	$85
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	239	435	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	66	1,757	$1,014,265
Revlimid	Lenalidomide	52	1,358	$862,946
Ibrance	Palbociclib	29	812	$500,420
Doptelet	Avatrombopag Maleate	13	390	$490,375
Lonsurf	Trifluridine/Tipiracil Hcl	22	616	$355,374

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$611	Dendreon Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmad Shaker, M.D.?

Tedicare shows public-source Medicare data for Ahmad Shaker, M.D. (NPI 1174767917), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmad Shaker, M.D. have ACO affiliation data?

Ahmad Shaker, M.D. is shown with ACO affiliation data for Pearl Network, LLC (REACH, ACO ID D0243).

What billing organization is linked to Ahmad Shaker, M.D.?

Ahmad Shaker, M.D. is linked to BAYCARE MEDICAL GROUP, INC. (billing NPI 1043269871) in the available physician profile data.

Does Ahmad Shaker, M.D. have Open Payments data?

Ahmad Shaker, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.